PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass.
PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass.
复制标题
中国绝经后低骨量女性PFN1基因多态性及对阿仑膦酸钠治疗的骨密度反应
DOI：
10.2147/pgpm.s344818
复制
发表时间：
2021
影响因子：
1.9
通讯作者：
Zhang Z
中科院分区：
文献类型：
--
作者：
Zhao J;Liu L;Lv S;Wang C;Yue H;Zhang Z
阿仑膦酸钠是一种广泛使用的抗肿瘤药物。PFN 1基因是新发现的早发性佩吉特病致病基因。本研究的目的是研究该基因的遗传变异是否会影响阿仑膦酸钠治疗绝经后低骨量女性的临床疗效。对PFN 1基因7个单核苷酸多态性位点进行基因分型。共有500名绝经后骨质疏松症或骨量减少的妇女被纳入。所有参与者每周服用阿仑膦酸钠70 mg，持续12个月。共有466例受试者完成了随访。分别于治疗前和治疗后测量腰椎、股骨颈和全髋的骨密度。治疗12个月后，腰椎、股骨颈和全髋骨密度均显著增加（P均< 0.001），平均增加率分别为4.72 ± 5.31%、2.08 ± 4.45%和2.42 ± 3.46%。基线时，不同基因型组间腰椎、股骨颈和全髋骨密度差异无统计学意义（P > 0.05）。我们没有发现PFN 1的基因型或单倍型与阿仑膦酸钠治疗的BMD反应之间存在任何显著相关性。PFN 1基因多态性可能不是中国低骨量妇女对阿仑膦酸钠治疗反应的主要因素。
Alendronate is a widely used anti-osteoporotic drug. PFN1 gene is a newly identified early-onset Paget’s disease pathogenic gene. The purpose of this study is to study whether the genetic variations in this gene affect the clinical efficacy of alendronate in postmenopausal Chinese women with low bone mass. Seven single nucleotide polymorphisms in PFN1 gene were genotyped. A total of 500 postmenopausal women with osteoporosis or osteopenia were included. All participants were treated with weekly alendronate 70 mg for 12 months. A total of 466 subjects completed the follow-up. Bone mineral density (BMD) of lumbar spine, femoral neck and total hip were measured at baseline and after treatment. After 12 months of treatment, the BMD of lumbar spine, femoral neck and total hip all increased significantly (all P < 0.001), with an average increase of 4.72 ± 5.31%, 2.08 ± 4.45%, and 2.42 ± 3.46%, respectively. At baseline, there were no significant differences in BMD at lumbar spine, femoral neck and total hip between different genotype groups (P > 0.05). We failed to identify any significant association between the genotypes or haplotypes of PFN1 and the BMD response to alendronate therapy. Genetic polymorphisms of PFN1 may not be a major contributor to the therapeutic response to alendronate treatment in Chinese women with low bone mass.